Literature DB >> 16220982

Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor.

David R Coleman1, Zhiyong Ren, Pijus K Mandal, Arlin G Cameron, Garrett A Dyer, Seema Muranjan, Martin Campbell, Xiaomin Chen, John S McMurray.   

Abstract

Signal transducer and activator of transcription 3 (Stat3) is a cytosolic transcription factor that relates signals from the cell membrane directly to the nucleus where it, in complex with other proteins, initiates the transcription of antiapoptotic and cell cycling genes, e.g., Bcl-x(L) and cyclin D1. In normal cells Stat3 transduces signals from cytokines such as IL-6 and growth factors such as the epidermal growth factor. Stat3 is constitutively activated in a number of human tumors. Antisense and dominant negative gene delivery result in apoptosis and reduced cell growth, thus this protein is an attractive target for anticancer drug design. As part of our research on the design of Src homology 2 (SH2) directed peptidomimetic inhibitors of Stat3, in this paper we describe structure-activity relationship studies that provide information on the nature of peptide-protein interactions of a high-affinity phosphopeptide inhibitor of Stat3 dimerization and DNA binding, Ac-Tyr(PO3H2)-Leu-Pro-Gln-Thr-Val-NH2, peptide 1. There is a hydrophobic surface on the SH2 domain that can accommodate lipophilic groups on the N-terminus. Of the amino acids tested, leucine provided the highest affinity at pY+1 and its main chain NH is involved with a hydrogen bond with Stat3, presumably Ser636. cis-3,4-Methanoproline is optimal as a backbone constraint at pY+2. The side chain amide protons of Gln are required for high-affinity interactions. The C-terminal dipeptide, Thr-Val, can be replaced with groups ranging in size from methyl to benzyl. We synthesized a phosphopeptide incorporating groups that provided increases in affinity at each position. Thus, hydrocinnamoyl-Tyr(PO3H2)-Leu-cis-3,4-methanoPro-Gln-NHBn, 50, was the highest affinity peptide, exhibiting an IC50 of 125 nM versus 290 nM for peptide 1 in a fluorescence polarization assay.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16220982     DOI: 10.1021/jm050513m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  43 in total

1.  Solid-phase synthesis of Stat3 inhibitors incorporating O-carbamoylserine and O-carbamoylthreonine as glutamine mimics.

Authors:  Pijus K Mandal; Patricia A Heard; Zhiyong Ren; Xiaomin Chen; John S McMurray
Journal:  Bioorg Med Chem Lett       Date:  2006-11-06       Impact factor: 2.823

Review 2.  Targeting STAT3 in cancer: how successful are we?

Authors:  Peibin Yue; James Turkson
Journal:  Expert Opin Investig Drugs       Date:  2009-01       Impact factor: 6.206

3.  Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling.

Authors:  Pijus K Mandal; Donald Limbrick; David R Coleman; Garrett A Dyer; Zhiyong Ren; J Sanderson Birtwistle; Chiyi Xiong; Xiaomin Chen; James M Briggs; John S McMurray
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

Review 4.  Therapeutic modulators of STAT signalling for human diseases.

Authors:  Gabriella Miklossy; Tyvette S Hilliard; James Turkson
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

5.  Crystal structure of the three tandem FF domains of the transcription elongation regulator CA150.

Authors:  Ming Lu; Jun Yang; Zhiyong Ren; Subir Sabui; Alexsandra Espejo; Mark T Bedford; Raymond H Jacobson; David Jeruzalmi; John S McMurray; Xiaomin Chen
Journal:  J Mol Biol       Date:  2009-08-04       Impact factor: 5.469

6.  Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.

Authors:  Jianyong Chen; Longchuan Bai; Denzil Bernard; Zaneta Nikolovska-Coleska; Cindy Gomez; Jian Zhang; Han Yi; Shaomeng Wang
Journal:  ACS Med Chem Lett       Date:  2010-05-13       Impact factor: 4.345

Review 7.  Cancer-associated myeloproliferation: old association, new therapeutic target.

Authors:  Ryan A Wilcox
Journal:  Mayo Clin Proc       Date:  2010-07       Impact factor: 7.616

8.  Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.

Authors:  Pijus K Mandal; Fengqin Gao; Zhen Lu; Zhiyong Ren; Rajagopal Ramesh; J Sanderson Birtwistle; Kumaralal K Kaluarachchi; Xiaomin Chen; Robert C Bast; Warren S Liao; John S McMurray
Journal:  J Med Chem       Date:  2011-04-26       Impact factor: 7.446

Review 9.  Targeting SH2 domains in breast cancer.

Authors:  Pietro Morlacchi; Fredika M Robertson; Jim Klostergaard; John S McMurray
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

10.  Conformational determinants of phosphotyrosine peptides complexed with the Src SH2 domain.

Authors:  Joseph Nachman; Gerry Gish; Cristina Virag; Tony Pawson; Régis Pomès; Emil Pai
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.